United Capital Financial Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$20.2M Sell
144,688
-26,123
-15% -$3.66M 0.12% 142
2025
Q4
$21M Sell
170,811
-6,785
-4% -$825K 0.13% 144
2025
Q3
$19.7M Sell
177,596
-3,695
-2% -$420K 0.14% 130
2025
Q2
$20.1M Sell
181,291
-7,743
-4% -$824K 0.16% 117
2025
Q1
$21.2M Sell
189,034
-14,227
-7% -$1.47M 0.18% 109
2024
Q4
$18.8M Sell
203,261
-43,103
-17% -$3.88M 0.16% 116
2024
Q3
$20.7M Sell
246,364
-7,802
-3% -$595K 0.17% 118
2024
Q2
$17.4M Sell
254,166
-10,921
-4% -$729K 0.15% 131
2024
Q1
$19.4M Sell
265,087
-38,317
-13% -$2.95M 0.16% 127
2023
Q4
$24.6M Sell
303,404
-303,600
-50% -$23.6M 0.2% 106
2023
Q3
$45.5M Sell
607,004
-44,680
-7% -$3.44M 0.3% 72
2023
Q2
$50.2M Sell
651,684
-28,805
-4% -$2.3M 0.27% 74
2023
Q1
$56.5M Sell
680,489
-13,365
-2% -$1.11M 0.32% 64
2022
Q4
$59.6M Sell
693,854
-19,762
-3% -$1.56M 0.33% 65
2022
Q3
$44M Buy
713,616
+6,377
+0.9% +$402K 0.26% 78
2022
Q2
$43.7M Buy
707,239
+482
+0.1% +$29.8K 0.24% 84
2022
Q1
$42M Buy
706,757
+10,732
+2% +$686K 0.2% 102
2021
Q4
$50.5M Buy
696,025
+27,354
+4% +$1.88M 0.23% 90
2021
Q3
$46.7M Buy
668,671
+18,941
+3% +$1.33M 0.23% 87
2021
Q2
$44.7M Buy
649,730
+34,314
+6% +$2.29M 0.23% 91
2021
Q1
$39.8M Buy
615,416
+26,645
+5% +$1.72M 0.22% 100
2020
Q4
$34.3M Buy
588,771
+50,106
+9% +$3.02M 0.21% 104
2020
Q3
$34M Buy
538,665
+51,870
+11% +$3.6M 0.22% 104
2020
Q2
$37.5M Buy
486,795
+32,289
+7% +$2.47M 0.27% 82
2020
Q1
$33.6M Sell
454,506
-33,013
-7% -$2.28M 0.28% 78
2019
Q4
$31.7M Buy
487,519
+44,993
+10% +$2.93M 0.2% 107
2019
Q3
$28M Buy
442,526
+23,544
+6% +$1.54M 0.2% 115
2019
Q2
$28.3M Buy
418,982
+33,072
+9% +$2.18M 0.19% 117
2019
Q1
$25.1M Buy
385,910
+152,733
+66% +$10.2M 0.18% 124
2018
Q4
$14.6M Sell
233,177
-12,903
-5% -$902K 0.12% 183
2018
Q3
$19M Sell
246,080
-314,379
-56% -$23.7M 0.13% 165
2018
Q2
$39.7M Buy
560,459
+338,290
+152% +$23.9M 0.3% 72
2018
Q1
$16.6M Sell
222,169
-141,083
-39% -$11.2M 0.13% 183
2017
Q4
$26.3M Buy
363,252
+28,674
+9% +$2.18M 0.21% 111
2017
Q3
$27.1M Buy
334,578
+14,643
+5% +$1.12M 0.23% 104
2017
Q2
$22.6M Sell
319,935
-16,118
-5% -$1.07M 0.2% 113
2017
Q1
$22.8M Buy
336,053
+101,532
+43% +$7.14M 0.21% 104
2016
Q4
$16.8M Sell
234,521
-9,814
-4% -$729K 0.16% 139
2016
Q3
$19.3M Buy
244,335
+18,578
+8% +$1.51M 0.19% 123
2016
Q2
$18.7M Buy
225,757
+4,124
+2% +$366K 0.19% 114
2016
Q1
$20.4M Buy
221,633
+11,644
+6% +$1.05M 0.22% 87
2015
Q4
$21.2M Buy
209,989
+4,042
+2% +$421K 0.24% 84
2015
Q3
$20.2M Buy
205,947
+22,080
+12% +$2.45M 0.24% 77
2015
Q2
$21.5M Buy
183,867
+793
+0.4% +$86.7K 0.25% 95
2015
Q1
$18.4M Buy
183,074
+34,745
+23% +$3.53M 0.22% 109
2014
Q4
$14M Buy
148,329
+46,528
+46% +$4.81M 0.21% 118
2014
Q3
$10.8M Sell
101,801
-7,550
-7% -$739K 0.19% 137
2014
Q2
$9.07M Buy
109,351
+33,640
+44% +$2.62M 0.17% 160
2014
Q1
$5.37M Buy
+75,711
New +$5.94M 0.11% 202
2013
Q4
Sell
-3,432
Closed -$216K 691
2013
Q3
$216K Buy
+3,432
New +$205K 0.01% 619

Other funds holding GILD

United Capital Financial Advisors's GILD Position: Q1 2026 in Review

United Capital Financial Advisors reduced its Gilead Sciences (GILD) stake by 15% in Q1 2026, selling an estimated $3.66M and leaving 144,688 shares worth $20.2M. The position accounts for 0.12% of the portfolio, ranked #142.

United Capital Financial Advisors first reported a position in GILD in Q3 2013 and has held it in 50 quarters since. The position peaked at $59.6M in Q4 2022. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • United Capital Financial Advisors held 144,688 shares of Gilead Sciences worth $20.2M as of Q1 2026.
  • United Capital Financial Advisors sold 26,123 Gilead Sciences shares in Q1 2026, an estimated $3.66M.
  • Gilead Sciences made up 0.12% of United Capital Financial Advisors's portfolio in Q1 2026, its #142 holding.
  • United Capital Financial Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 50 quarters since.
  • United Capital Financial Advisors's Gilead Sciences position peaked at $59.6M in Q4 2022.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on United Capital Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.